Foster & Motley Inc. Decreases Holdings in McKesson Corporation $MCK

Foster & Motley Inc. decreased its stake in McKesson Corporation (NYSE:MCK) by 9.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,753 shares of the company’s stock after selling 1,356 shares during the period. Foster & Motley Inc.’s holdings in McKesson were worth $11,282,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in MCK. J.W. Cole Advisors Inc. increased its holdings in shares of McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after purchasing an additional 1,329 shares during the period. Cullen Investment Group LTD. lifted its stake in shares of McKesson by 550.4% in the fourth quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock valued at $3,811,000 after purchasing an additional 3,952 shares during the period. Private Wealth Partners LLC boosted its stake in shares of McKesson by 5.6% during the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after acquiring an additional 1,682 shares in the last quarter. AlphaQuest LLC boosted its position in McKesson by 91.2% during the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares in the last quarter. Finally, CW Advisors LLC boosted its position in shares of McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after buying an additional 8,130 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MCK has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Raymond James Financial set a $970.00 price objective on shares of McKesson in a research note on Thursday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a research report on Wednesday, December 10th. Evercore reiterated an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a research report on Thursday, January 29th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $960.93.

McKesson Price Performance

Shares of MCK opened at $860.37 on Tuesday. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The stock has a fifty day moving average price of $908.02 and a 200 day moving average price of $841.69. The company has a market cap of $105.39 billion, a P/E ratio of 24.74, a PEG ratio of 1.38 and a beta of 0.38.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. During the same period last year, the firm earned $8.03 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio is currently 9.43%.

Insider Activity at McKesson

In other McKesson news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at $3,214,530. This trade represents a 45.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Maria Martinez sold 349 shares of McKesson stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the sale, the director owned 301 shares of the company’s stock, valued at approximately $282,900.87. This represents a 53.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,868 shares of company stock valued at $3,743,820. Corporate insiders own 0.08% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.